http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Bulent Inanc ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
FEASIBILITY OF LANDFILL RECLAMATION IN JAPAN
( Bulent Inanc ),( Masato Yamada ),( Tomonori Ishigaki ),( Ohkochi Yumiko ),( Shino Mohri ),( Y. Inoue ),( Yusaku Ono ),( Masanao Nagamori ) 한국폐기물자원순환학회 2002 APLAS Vol.2002 No.1
In this paper, current situation of landfilling in Japan is presented, and future research need for landfill reclamation is discussed. Japan, with very high land utilization, has very little landfill capacity left, and acquiring a new landfill site is a challenging task due to objection from local residents and high land cost. Industrial and municipal waste landfills have left only less than three and ten years capacity, respectively. On the other hand, on march 1998, Ministry of Health and Welfare has published a list of 538 inappropriate municipal landfill sites with no liner, leachate treatment facility, or both, and requiring immediate corrective action. Therefore, early stabilization and reclamation are now crucially important for combating the final disposal problem.
-
Bozkurt, Oktay,Berk, Veli,Kaplan, Muhammed Ali,Cetin, Bulent,Ozaslan, Ersin,Karaca, Halit,Inanc, Mevlude,Duran, Ayse Ocak,Ozkan, Metin Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.6
Background: Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer. Although overall and progression free survivals have increased in recent years with the use of new generation drugs, predictive factors that would further improve the outcomes are needed. Previous studies have demonstrated the relation between post-treatment increase in mean corpuscular volume (MCV) and predicting therapy response as well as survival. The present study investigated the clinical impact of MCV elevation in metastatic breast cancer patients treated with capecitabine. Materials and Methods: The data of a total of 82 patients from three centers followed between June 2005 and June 2013 were retrospectively analyzed. The demographic data and hormone receptor status of the patients, as well as initial examination before and after treatment and data concerning progression were recorded. MCV ${\geq}100$ fl was considered as macrocytosis. Capecitabine was given at a dose of $2500mg/m^2$ daily for 14 days every three weeks. Pre-treatment and post-treatment MCV and other parameters of complete blood count were recorded. Post-treatment initial evaluation was performed after 2 cycles of therapy. Results: The median age of the patients was 46.5 years (range 26-72 years) and 54% were premenopausal. Performance status was ECOG 0 and 1 in 81 (99%) patients. The median number of cycles for capecitabine therapy was 5 (min-max: 2-18). The median ${\Delta}MCV$ level (post-treatment values at sixth week - baseline) was 6.4. Whilst ${\Delta}MCV$ was ${\geq}6.4$ in 42 patients, it was <6.4 in 40 patients. Clinical benefit (complete response+partial response+stable disease) was observed in 37 (88%) of 42 patients with a median ${\Delta}MCV$ ${\geq}6.4$ and in 30 (75%) of 40 patients with ${\Delta}MCV$ <6.4 with no statistically significant difference (p=0.158). No significant difference was determined between the group with ${\Delta}MCV$ ${\geq}6.4$ and the group with ${\Delta}MCV$ <6.4 in terms of progression-free survival (11 vs 12 months) (p=0.55) and overall survival (20 months vs. 24 months) (p=0.11). Conclusions: The identification of new predictive markers in metastatic breast cancer is very important. In some recent studies, increase in MCV has been suggested as a marker in tumor response. In the present study, however, no significant difference was determined between tumor response and increase in MCV. Further studies including higher numbers of patients are needed to determine whether increase in MCV is a predictive marker or not.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
